September 19, 2017

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) gets U.S. approval to purchase Rite Aid stores for $4.4 billion

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) gets U.S. approval to purchase Rite Aid stores for $4.4 billion in its fourth attempt, and this happened after a last-minute reduction of the number of stores and price.

On Tuesday, the Deerfield-based drugstore chain said that it secured clearance for a revised deal under which it will buy 1,932 Rite Aid stores for $4.38 billion. That’s about 250 fewer stores than under a previous proposal, which totaled $5.18 billion.

Walgreens Boots Alliance, Inc. (NASDAQ:WBA)’s stock on Tuesday traded at beginning with a price of $82.97 and when day-trade ended the stock finally plummeted -1.68% to reach at $81.21. Analyst’s mean target price for WBA is $92.95 while analysts mean recommendation is 2.00. Stock value has moved between $75.19 – 88.27 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked WBA based on current scenarios. Stock has got OUTPERFORM rating from 10 analyst(s) whereas last month 9 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 10 analyst(s) given BUY rating to the stock. Company fiscal year is ending in August and analysts’ consensus recommendation is Outperform for WBA and estimated EPS for next quarter is $ 1.30 .

Walgreens Boots Alliance, Inc. (NASDAQ:WBA) yearly performance is 0.49% and net profit margin is 3.70%. Annual EPS Growth of past 5 years is 5.40%. The current share price indicates that stock is -7.72% away from its one year high and is moving 8.02% ahead of its 52-week low.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO)‘s stock on Tuesday traded at beginning with a price of $1.49 and when day-trade ended the stock finally popped up 11.03% to reach at $1.61. Analyst’s mean target price for EBIO is $12.00 while analysts mean recommendation is 2.00. Stock value has moved between $0.9 – 4.03 in last one year.

Analyst’s ratings play a very important role in outlining a stock’s performance. Let us check out how analysts have ranked EBIO based on current scenarios. Stock has got OUTPERFORM rating from 1 analyst(s) whereas last month 1 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 0 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for EBIO and estimated EPS for next quarter is $ .

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) yearly performance is -50.46% and net profit margin is 8.60%. Annual EPS Growth of past 5 years is 15.00%. The current share price indicates that stock is -60.15% away from its one year high and is moving 78.89% ahead of its 52-week low.

On 19 September 2017, Transocean Ltd. (NYSE:RIG) stock price started the day at $9.35 and moved between $9.19 – 9.38 to finally close at $9.35. RIG’s distance from 20 day simple moving average is 11.19% and distance from 50-Day simple moving average is 11.29%. In last 4 months performance of RIG was 14.02% while its price to sale ratio is 1.07 and price to book ratio is 0.26.

Analysts expect Transocean Ltd. (NYSE:RIG) to report $ -0.07 EPS and has got OUTPERFORM rating from 7 of Thomson Reuters analysts and 8 analyst(s) given UNDERPERFORM rating. Analyst’s mean target price for RIG is $10.78 while analysts mean recommendation is 3.10. Firm LT growth rate is estimated as 714.25 %.

T-Mobile US, Inc. (NASDAQ:TMUS)’s stock on Tuesday traded at beginning with a price of $62.01 and when day-trade ended the stock finally popped up 5.86% to reach at $65.42. Analyst’s mean target price for TMUS is $71.68 while analysts mean recommendation is 2.10. Stock value has moved between $44.5 – 68.86 in last one year.

Stock has got OUTPERFORM rating from 13 analyst(s) whereas last month 13 analyst(s) have given outperform rating. SELL rating has been given by 0 analyst(s) and 8 analyst(s) given BUY rating to the stock. Company fiscal year is ending in December and analysts’ consensus recommendation is Outperform for TMUS and estimated EPS for next quarter is $ 0.44 .

T-Mobile US, Inc. (NASDAQ:TMUS) yearly performance is 42.43% and net profit margin is 5.00%. Annual EPS Growth of past 5 years is 17.00%. The current share price indicates that stock is -5.02% away from its one year high and is moving 47.04% ahead of its 52-week low.

Leave a Reply

Your email address will not be published. Required fields are marked *